(Reuters) – The U.S. Food and Drug Administration on Saturday declined to approve Zealand Pharma’s drug for the prevention and treatment of low blood sugar in children with a genetic disorder.
(Reporting by Mrinmay Dey, Bhanvi Satija and Sriparna Roy in Bengaluru; Editing by Krishna Chandra Eluri and Tomasz Janowski)
